Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET

Company Participants

Lisa Conte - Founder, President & Chief Executive Officer
Pravin Chaturvedi - Chief Scientific Officer
Carol Lizak - Chief Financial Officer

Operator

[Call Starts Abruptly] before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not make -- achieve scientific objectives or meet changing regulatory requirements.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those complicated in such forward-looking statements. These statements are based on current available information and management's current assumptions, expectations and projections about future events.

While management believes its assumptions, expectations and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and Risk Factors sections in the company's Form 10-K in the year 2023, which was filed on April 1, 2024, and its other filings with the SEC, which are available on the Investor Relations section of Jaguar's website.

Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect your information, future events or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis with providing non-GAAP EBITDA and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items in these non-GAAP measures provide investors with additional information that reflects the basis upon which the company management assesses and operates the business.

These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for or superior to measures of financial performance and conformality with GAAP.

As a reminder, today's conference call is being recorded. And at this time, it is my pleasure to turn the call over to Lisa Conte, Jaguar Health's Founder, President and Chief Executive Officer.

Lisa, the floor is yours.

Lisa Conte